Latest News

    • Eyestem announces a significant milestone against an incurable form of blindness which affects over 150 M people globally (About Dry AMD)

    • We are delighted to share positive animal efficacy results from Dr. Trevor McGill About Dr. Trevor McGillat the Oregon Health and Science University for Eyecyte-RPE: our lead product for treatment of Dry AMD (macular degeneration) 

    • As per Dr.McGill "Eyecyte-RPE providedsignificant beneficial effects on the degenerating retina in RCS ratswithout any significant safety concerns suggesting this cell type may have significant therapeutic value in human retinal degenerative disease".  
    • Dr. Jogin Desai, Founder and CEO, Eyestem Research said " The POC results have shown significant preservation of photoreceptors and functional rescue of vision and the results are at par or better than most published data globally. We will be using this momentum to now aggressively move forward into  GLP toxicology, larger efficacy and GMP production for our product for Dry AMD." 
    • Eyestem listed among 30 entrepreuners and enables of Innovation at the Bengaluru Tech Summit

      Eyestem  is honoured to be amoung the 30 entrepreneurs and enablers in a special AR edition book of Innovate Bengaluru. The book was launched at the Bengaluru Tech Summit by the Chief Minister of Karnataka, Shri H.D. Kumaraswamy.

      Dr. Jogin Desai, Founder and CEO of Eyestem said " Bengaluri is one of the most dynamic startup ecosystems worldwide and we are delighted to be part of an elite list of innovators in such a city".

      For more details, please visit https://innovationhubindia.com/bengaluru/

       

    • Eyestem files a patent for a unified protocol for co-creation of Retinal Pigment Epithelium progenitors (RPE-P) and Photoreceptor progenitors (PR-P)

      Eyestem Research (ERPL), a company engaged in creating cell therapies for incurable diseases of the eye today filed a patent to create both its products: RPE-P and PR-P: through a unified protocol. By employing this protocol, ERPL has demonstrated that a large part of the process of the creation of the two products remain exactly the same.

      Having a unified methodology will allow ERPL to create both products with a scalable and affordable process. This is a highly significant advancement whose potential will be fully realized in the coming years when the company moves to GMP production at scale for patients.

      For further information, please write to info@eyestem.com

    • Eyestem Research Private Limited enters into a research collaboration with Nxcell Inc. for testing its Photoreceptor progenitors (PR-P) in the Crx mouse model

      Eyestem Research (ERPL), a company engaged in creating cell therapies for incurable diseases of the eye, today announced a research collaboration with Nxcell Inc. for testing its cell based product for Retinitis Pigmentosa. Eyestem’s product is a patented cell suspension of Photoreceptor progenitors (PR-P) and will be tested for efficacy in the Crx knockout mouse model.

      The collaboration between ERPL and Nxcell will be enabled by Dr. Deepak Lamba, Associate Professor for vision research at the Buck Institute, Los Angeles. Dr. Lamba serves on the scientific board of Eyestem and has published several seminal papers in efficacy of photoreceptors in rescuing and reversing vision loss in mice models. The outcome of this experiment will enable ERPL to create efficacy data that is globally acceptable and move its product forward in clinical trials.

      For more information, please e-mail us at info@eyestem.com

    • Eyestem Research Private Limited enters into a research collaboration with Oregon Health & Science University to test its Retinal Pigment Epithelium progenitor (RPE-P) product for Age-related Macular Degeneration in the RCS rat model

      Eyestem Research (ERPL), a company engaged in creating cell therapies for incurable diseases of the eye, today announced a research collaboration with OHSU in Portland, Oregon, for testing its cell based product for Age-related Macular Degeneration. Eyestem’s product is a patented cell suspension of Retinal Pigment Epithelium progenitors (RPE-P) and will be tested for efficacy in the Royal College of Surgeons (RCS) rat model.
      The collaboration will enable ERPL to work with Trevor McGill, Ph.D., a recipient of the 2017 Carolyn K. McGillvray Award for Macular Degeneration Research. Dr. McGill’s expertise with the disease model and his involvement in several IND-enabling studies will enable ERPL to collect data that is globally acceptable for the efficacy of its RPE-P product.

      For more information, please e-mail us at info@eyestem.com